Mill Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Mill Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.6M	Sell	42,868 -3,500	-8%	-$204K	0.2%	51
2025 Q4	$2.5M	Hold	46,368	–	–	0.18%	54
2025 Q3	$2.09M	Sell	46,368 -1,100	-2%	-$51.4K	0.16%	56
2025 Q2	$2.2M	Hold	47,468	–	–	0.17%	56
2025 Q1	$2.9M	Sell	47,468 -65	-0.1%	-$3.79K	0.23%	47
2024 Q4	$2.69M	Sell	47,533 -1,100	-2%	-$61.5K	0.21%	51
2024 Q3	$2.52M	Sell	48,633 -1,405	-3%	-$65.9K	0.2%	53
2024 Q2	$2.08M	Sell	50,038 -1,495	-3%	-$66.9K	0.17%	57
2024 Q1	$2.79M	Sell	51,533 -4,268	-8%	-$217K	0.23%	53
2023 Q4	$2.86M	Hold	55,801	–	–	0.26%	48
2023 Q3	$3.24M	Hold	55,801	–	–	0.32%	44
2023 Q2	$3.57M	Buy	55,801 +1,620	+3%	+$109K	0.34%	43
2023 Q1	$3.76M	Sell	54,181 -2,715	-5%	-$191K	0.38%	42
2022 Q4	$4.09M	Hold	56,896	–	–	0.45%	41
2022 Q3	$4.04M	Hold	56,896	–	–	0.47%	41
2022 Q2	$4.38M	Hold	56,896	–	–	0.49%	41
2022 Q1	$4.16M	Hold	56,896	–	–	0.4%	42
2021 Q4	$3.55M	Buy	+56,896	New	+$3.34M	0.36%	46

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mill Capital Management's BMY Position: Q1 2026 in Review

Mill Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 7.5% in Q1 2026, selling an estimated $204K and leaving 42,868 shares worth $2.6M. The position accounts for 0.2% of the portfolio, ranked #51.

Mill Capital Management first reported a position in BMY in Q4 2021 and has held it in 18 quarters since. The position peaked at $4.38M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Mill Capital Management held 42,868 shares of Bristol-Myers Squibb worth $2.6M as of Q1 2026.
Mill Capital Management sold 3,500 Bristol-Myers Squibb shares in Q1 2026, an estimated $204K.
Bristol-Myers Squibb made up 0.2% of Mill Capital Management's portfolio in Q1 2026, its #51 holding.
Mill Capital Management first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 18 quarters since.
Mill Capital Management's Bristol-Myers Squibb position peaked at $4.38M in Q2 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Mill Capital Management's 13F filing for Q1 2026, filed 4 May 2026.